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Abstract Structural mean models (SMMs) have been proposed for estimating
causal treatment effects in the presence of non-ignorable non-compliance in clinical
trials. To obtain a valid causal estimate, we must impose several assumptions. One
of these is the correct specification of the parametric part of the SMMs. Model
checking is an important task for data analysts to detect any departure of an assumed
model from the true one. However, little work has been done on the goodness-of-fit
(GOF) test for the SMMs. In this article, we propose a global GOF test of SMMs.
Numerical studies show the proposed test can control type I errors if the SMM is
correctly specified. Furthermore, the proposed test detects non-linear effect modi-
fication of continuous covariates powerfully, while an existing test does not. We
apply the proposed method to data derived from a randomized trial to evaluate the
impact of a primary care-based intervention on depression.
Keywords Causal inference  Effect modification  Goodness-of-fit test 
Instrumental variable  Non-compliance  Structural mean models
1 Introduction
In a typical clinical trial, patients are randomly assigned to different groups with
specific treatments; each patient is expected to receive that treatment throughout
follow-up to assess its effect on some outcome. However, most clinical trials are not
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ideal; patients often fail to adhere to their assigned treatment and switch to another
trial treatment. Such non-compliance with assigned treatments is a common feature
of clinical trials.
Robins (1994) developed structural mean models (SMMs) to cope with non-
compliance without having to specify the mechanism of non-ignorable non-
compliance (Rubin 1976) using randomization as an instrumental variable. One
attractive feature of SMMs is their modeling flexibility, which allows for the
expression of the causal effect of received treatments as a function of treatments and
covariates through a finite number of unknown causal parameters without
specifying the conditional expectation of potential outcomes under the control
treatment. SMMs have now been proposed for continuous, discrete, and binary
outcomes (Robins 1994; Vansteelandt and Goetghebeur 2003), and related
structural distribution models have been developed for survival outcomes (Mark
and Robins 1993; Loeys and Goetghebeur 2003).
To obtain a valid causal estimate, we must impose several assumptions. One of
these is the correct model specification of the structural model. This can be
numerically checked by evaluating the goodness of fit (GOF) of postulated SMMs
to the data. For continuous outcomes, Comte et al. (2009) developed a test of the
interaction between treatment and a baseline covariate, and Fischer et al. (2011)
proposed a local GOF test which can detect a linear effect modification with a
covariate but cannot detect a non-linear effect modification. Taguri et al. (2014)
recently proposed a model selection criterion as an extension of Akaike’s
information criterion (Akaike 1973) for evaluating the relative fitting of candidate
models using the expected Kullback–Leibler distance as a metric. However, none of
them proposed a global GOF test which can detect any misspecifications of the
assumed model structure.
In general, the validity of the estimating equations depends on whether the
parametric part of the SMM is correctly specified. If the SMM is misspecified, the
resultant estimating equations deviates in expected value from zero, thus an
inconsistent estimator will be yielded. To get a valid inference, it is desirable to
assess the unbiasedness of the estimating equations. Diagnostic tools such as
residuals have been widely used to assess the appropriateness of a generalized linear
model (Su and Wei 1991; Lin et al. 2002). However, such methods cannot apply to
non-compliance data with an instrumental variable. The aim of this article is to
develop a global GOF test of linear SMMs. The idea is based on testing for the
unbiasedness of g-estimating equations (Robins 1994). The residual processes will
be constructed in the same spirit of Su and Wei (1991), Lin et al. (2002), Pan and
Lin (2005), and Chen and Qin (2014). Under the null hypothesis that g-estimating
equations are unbiased, the residual processes will fluctuate about zero. Thus a large
absolute value of the residuals leads to the conclusion of model misspecification.
Numerical studies show that the proposed test can control type I errors if the SMM
is correctly specified. Furthermore, the proposed test detects non-linear effect
modification of continuous covariates with high probability, while Fischer et al.’s
test does not.
The reminder of this article is as follows. In Sect. 2, we briefly overview the
SMMs and the g-estimation procedure. In Sect. 3, we review the method by Fischer
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et al. (2011) and propose a GOF test. In Sect. 4, we present a simulation study to
investigate the performance of our proposed test. In Sect. 5, we apply the proposed
method to data derived from a randomized trial to evaluate the impact of a primary
care-based intervention on depression. Finally, in Sect. 6, we conclude with a
discussion.
2 Structural mean models
We consider a randomized two-arm trial, where n patients are randomized to one of
the two treatments. Let R be the indicator of treatment assignment, equal to 1 (0) for
the test (control) treatment. Let A be the actual treatment whether an individual
received test treatment (1: test, 0: control), X is the vector of baseline covariates,
and Y is the continuous outcome measured at the end of the trial. We assume the
observed data Oi = (Ri, Xi
T, Ai, Yi)
T, i = 1,…, n are n independent and identically
distributed random vectors. Thus, we omit the subscript i unless necessary. In
contrast to the observed outcome variable Y, we define Yra with r, a = 0, 1 as the
potential outcome (Rubin 1974) that would be observed if possibly contrary to the
fact that R were set to r and A were set to a. We make the following three
assumptions to estimate causal treatment effects:
(A1) Stable Unit Treatment Value Assumption (SUTVA)
The potential outcome for each patient does not depend on the treatment
assigned or the treatment actually received by any other patient. SUTVA also
implies the consistency assumption, which means that a patient’s potential
outcome under his/her treatment is precisely his/her observed outcome. In
notation, SUTVA implies that
Y ¼ RAY11 þ R 1Að ÞY10 þ 1Rð ÞAY01 þ 1Rð Þ 1Að ÞY00:
(A2) Exclusion restriction
Treatment assignment only affects the outcome through its effect on
treatment received. This assumption implies that Yra = Ya with r, a = 0, 1.
Under this assumption, Y11 = Y01 = Y1 is the potential outcome under test
treatment, while Y10 = Y00 = Y0 is that under control treatment.
(A3) Randomization assumption
The random assignment R and Y0 are conditionally independent given
baseline covariates X, i.e., Y0
‘
R |X.
Furthermore, we assume that the average causal treatment effects follow linear
SMMs (Robins 1994; Goetghebeur and Vansteelandt 2005):
E½Y  Y0jA;X;R ¼ AZðX;RÞTh; ð1Þ
where Z(X, R) is a v-dimensional (v C 1) vector that depends on (X, R) and h is the
unknown v-dimensional causal parameter vector of interest. Note that from (1),
E Y1  Y0jA ¼ 1;X;R½  ¼ Z X;Rð ÞTh is the effect of the treatment on the treated
conditional on the baseline covariates and the randomization indicator (X, R). For
example, when Z(X, R)T = (1, XT), we allow for the possibility that the average
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causal effect on the treated is not constant with levels of X and changes linearly with
X.
Because the full data (Y1, Y0, A, R, X
T) is only partially observed for each patient
i, no regression methods for the complete data can be used to fit the model (1).
However, from (1) and the assumption A3, it follows that E½Y 
AZðX;RÞThjX;R ¼ E½Y0jX;R ¼ E½Y0jX: Using this, a consistent estimator of h
can be obtained from a class of unbiased g-estimating functions (Robins 1994):
wðhÞ ¼ ðR pÞwðXÞfUðhÞ  qðXÞg; ð2Þ
where p ¼ Pr½R ¼ 1jX ¼ Pr½R ¼ 1 is the randomization probability known by
design, UðhÞ ¼ Y  AZðX;RÞTh; w(X) is a v-dimensional vector function, and q(X)
is a scalar function. For some w(X) and q(X), a consistent estimator of h (called the
g-estimator) is analytically obtained by solving g-estimating equationsPn
i¼1 wiðhÞ ¼ 0; where wiðhÞ is the i-th sample value of wðhÞ: The optimal choices
for w(X) and q(X) from the viewpoint of efficiency that lead to a semiparametric
efficient estimator of h were derived by Robins (1994). Under the homoscedasticity
assumption that the error variance of the regression of U(h) on (R, X) is constant,
these choices are given by woptðXÞ ¼ doptðXÞE½ZðX;RÞjX and qoptðXÞ ¼
E½UðhÞjX; where dopt Xð Þ ¼ Pr A ¼ 1jR ¼ 1;X½ Pr A ¼ 1jR ¼ 0;X½  is called the
compliance score (Joffe and Brensinger 2003). dopt(X) upweights participants
characterized by X for whom the effect of treatment assignment on the treatment
received is large, thus contributing information to estimate the effect of the treat-
ment on the outcome. Since the optimal choices are unknown functions of X, it is
often assumed parametric models for dopt(X) in wopt(X) and q(X). In our simulation
and data analysis, we estimate Pr[A = 1|R, X] in dopt(X) by a logistic regression. We
assume qopt(X) is linear in X, which leads to an analytical estimator of h^ (Fischer
et al. 2011). A consistent variance estimator of h^ is obtained as
n1X^ðh^Þ1K^ðh^ÞðX^ðh^Þ1ÞT; where XðhÞ ¼ E½owðhÞ=ohT, KðhÞ ¼ var½wðhÞ:
3 Goodness of fit tests for structural mean models
3.1 Goodness of fit test proposed by Fischer et al. (2011)
Before discussing our method for assessing the fit of the SMM (1), we briefly review
the GOF test proposed by Fischer et al. (2011). Their methods are essentially based
on the fact that if model (1) is correctly specified, then the expected ‘‘treatment-
free’’ outcomes Uðh^Þ in both arms R = 1 and R = 0 will have the same regression
functions on X. The GOF test was conducted using the following linear regression
model for Uðh^Þ on (X, R):
E½Uðh^ÞjX;R ¼ b0 þ bT1X þ b2R þ bT3RX: ð3Þ
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To assess whether the model is a good fit, we conducted the test of the following
null hypothesis: H0 : b3 ¼ 0: If we find the interaction terms significant (that is, H0
is rejected), then there is an evidence for the lack of fit. Note that this GOF test
would not detect a non-linear effect modification by X because (3) includes only
linear terms of X. We additionally note that model misspecification will usually
occur in the model (3). To see this, let h* be the true value of h. For an arbitrary h,
the following equation holds by the SMM (1):
E½UðhÞjX;R ¼ E½Y0jX þ E½AjX;RZðX;RÞTðh  hÞ: ð4Þ
The third term of (4) with h ¼ h^will be apparently nonlinear in Xwhen A is binary
unless h^ ¼ h holds. In such cases, (3) is a misspecified model. This misspecification
could affect the power of the GOF test, although the size of the test should be
asymptotically equal to the nominal level because the third term of (4) with h ¼ h^ has
asymptotically zero expectation under the correct specification of (1).
3.2 Proposed goodness of fit test
Rather than assuming a parametric model for Uðh^Þ such as (3), we can construct a
GOF test in the spirit of Su and Wei (1991), Lin et al. (2002), Pan and Lin (2005),
and Chen and Qin (2014). The idea is based on testing for the unbiasedness of the g-
estimating equations under the correct model specification. To check the validity of




IðXi xÞðRi  pÞdoptðXiÞfUiðh^Þ  qoptðXiÞg; ð5Þ
where x is a real-valued vector of length v. Under the null hypothesis that the SMM
(1) is correctly specified, (5) has zero expectation for all values of x. Thus, a large
value of the following omnibus test statistic Gn ¼ supx2Rv jVnðxÞj leads to the
conclusion of model misspecification.
To make a GOF test, we need to specify the distribution of Vn(x). The
cumulative-sum process Vn(x) converges in distribution to a zero-mean Gaussian
process under the null hypothesis that the SMM (1) is correctly specified. Using the




IðXi xÞðRi  pÞdoptðXiÞfUiðhÞ  qoptðXiÞg þ gðx; hÞTn1=2ðh^ hÞ;
ð5Þ
where gðx; hÞ ¼ n1P
n
i¼1
IðXi xÞðRi  pÞdoptðXiÞoUiðhÞ=oh and A  B means
A-B = op (1). Using a similar Taylor expansion, we obtain
n1=2ðh^ hÞ ¼ XðhÞ1n1=2wiðhÞ; ð6Þ
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½IðXi xÞðRi  pÞdoptðXiÞfUiðhÞ  qoptðXiÞg
þ gðx; hÞTXðhÞ1wiðhÞ: ð7Þ
Although it is hard to specify the explicit distribution form of (7), Su and Wei
(1991) proposed a simulation-based method to approximate the null distribution of
Vn(x). The idea is as follows. Suppose that S1,…, Sn are independent and identically
distributed variables from F(S), with l = E[S] = 0 and r2 = E[S 2]\?, then
based on the central limit theorem, we have n1=2
Pn
i¼1 Si ! N 0; r2ð Þ. Let Z1,…, Zn
be independent standard normal random variables. Then conditional on the original






i Þ ! N 0; r2ð Þ. That is,
n1=2
Pn
i¼1 ZiSi has the same asymptotic distribution as that of n
1=2Pn
i¼1 Si.




½IðXi xÞðRi  pÞdoptðXiÞfUiðh^Þ  qoptðXiÞg
þ gðx; h^ÞT X^ðh^Þ1wiðh^Þ Zi; ð8Þ
where (Z1,…, Zn) is a random sample from N(0,1). To approximate the null dis-
tribution of Vn(x), we generate large number of samples (Z1,…, Zn) from N(0,1)
while fixing the data at their observed values.
4 A simulation study
In this section, the performance of the proposed method is evaluated via a
simulation study. The following data (R, X, A, Y) were generated as follows. Let X
be distributed as N(0,1) and the treatment assignment R be generated from
Bernoulli(0.5). Next, the received treatment A was assigned according to the logistic
model logit½PrðA ¼ 1jR;X; cÞ ¼ 1þ 4Rþ X þ c; where c follows N(0,0.25).
Then, outcome Y was generated from N(3X ? A(k0 ? k1X ? k2X
2) ? 0.5c, 0.25).
This leads to the true SMM: E[Y1 - Y0|A = 1, X] = k0 ? k1X ? k2X
2. The shared
random effect, c, gave rise to non-ignorable non-compliance. We set
(k0,k1,k2) = (3,0,0) for no effect modification by X, (k0,k1,k2) = (3,0.1,0),
(3,0.2,0), (3,0.3,0), (3,0.4,0), (3,0.5,0), (3,2,0), (3,5,0) for linear effect modifica-
tions, (k0,k1,k2) = (-0.2,0,0.4), (-0.4,0,0.8), (-0.6,0,1.2), (-0.8,0,1.6), (-1,0,2),
(-2,0,4), (-4,0,8) for quadratic effect modifications. We set the sample size
n = 500. For each setting, we ran 1000 simulations.
For the analysis of the simulated data, we assumed the main effect model:
E Y1  Y0jA ¼ 1;X½  ¼ h. We investigated four GOF tests: (i) Fischer: Fisher et al.’s
GOF test; (ii) V1n(x): proposed GOF test with VnðxÞ ¼ n1=2
Pn
i¼1 IðXi xÞ ðRi 
pÞUiðh^Þ; (iii) V2n(x): proposed GOF test with VnðxÞ ¼ n1=2
Pn
i¼1 IðXi xÞ ðRi 
pÞd^optðXiÞUiðh^Þ; (iv) V3n(x): proposed GOF test with VnðxÞ ¼




i¼1 IðXi xÞðRi  pÞd^optðXiÞfUiðh^Þ  q^optðXiÞg: For each test, the two-sided
significance level was set at 0.05.
Table 1 summarizes the empirical rejection probabilities by four methods. For no
effect modification case, all of the four GOF tests kept the nominal significance
level. For linear effect modification cases, the power of the all tests were increasing
as the true effect was increasing. Among the four methods, Fischer et al.’s test
performed the best in terms of the empirical power, although the power of the
proposed test with V3n(x) was only slightly lower than that of Fischer et al.’s test.
This is not surprising because our GOF test was an omnibus test using a
Kolmogorov-type test statistic. For quadratic effect modification cases, the power of
the proposed tests were also increasing as the true effect was increasing. On the
other hand, the power of the Fischer et al.’s test was not monotonically increasing
with the strength of the true effect. Among the three statistics for the proposed
method, V3n(x) performed by far the best. This indicates that using the optimal
nuisance functions dopt (X) and qopt (X) as described in Sect. 3.2 is very important
for the good performance of our proposed test.
5 Application
We now apply the proposed method to data derived from the PROSPECT
(Prevention of Suicide in Primary Care Elderly: Collaborative Trial) (Bruce and
Pearson 1999; Bruce et al. 2004). Data are available at http://research.bmh.
manchester.ac.uk/biostatistics/research/data. PROSPECT was a multi-site
Table 1 Empirical size and power of the GOF tests
Method
Pattern of the effect (k0,k1,k2) Fischer V1n(x) V2n(x) V3n(x)
No effect modification (3,0,0) 0.040 0.045 0.040 0.048
Linear effect modification (3,0.1,0) 0.109 0.046 0.042 0.108
(3,0.2,0) 0.341 0.046 0.044 0.295
(3,0.3,0) 0.608 0.048 0.048 0.588
(3,0.4,0) 0.837 0.049 0.049 0.803
(3,0.5,0) 0.943 0.056 0.056 0.930
(3,2,0) 1.000 0.081 0.146 1.000
(3,5,0) 1.000 0.195 0.574 1.000
Quadratic effect modification (-0.2,0,0.4) 0.715 0.046 0.039 0.579
(-0.4,0,0.8) 0.552 0.047 0.050 0.928
(-0.6,0,1.2) 0.510 0.047 0.081 0.976
(-0.8,0,1.6) 0.486 0.053 0.141 0.982
(-1,0,2) 0.522 0.054 0.234 0.986
(-2,0,4) 0.535 0.152 0.782 0.989
(-4,0,8) 0.535 0.420 0.984 0.990
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prospective, randomized trial designed to evaluate the impact of a primary care-
based intervention on reducing major risk factors (including depression) for suicide
in later life. Participants were recruited from 20 primary care practices in New York
City, Philadelphia and Pittsburgh regions. Ten pairs of practices were matched by
region (urban vs suburban/rural), affiliation, size, and population type. Within these
10 pairs, practices were randomly allocated to one of the two conditions. The two
conditions were either (a) an intervention based on treatment guidelines tailored for
the elderly with care management including antidepressant medication (R = 1) or
(b) treatment as usual (R = 0). For illustration purposes, here, we analyzed the data
as if interventions were randomly assigned at the individual level. We use these data
to assess the effect of antidepressant medication (A = 1: presence; A = 0: absence)
on the change of the Hamilton Depression Rating Scale (HDRS) (Hamilton 1960)
score at four months after randomization from baseline (Y). We use the baseline
score of the HDRS as a baseline covariate (X), and it is centered with the mean
value of the entire sample for estimation of SMMs.
Table 2 summarizes the analysis results. We started with an Intention-to-treat
(ITT) analysis and it indicated that the HDRS score at four months was significantly
lower in the intervention group than it was in the control group
(ITT effect¼E^½Y jR ¼ 1  E^½YjR ¼ 0 ¼ 3:62, 95 % confidence interval: -5.29
to -1.95). However, those who did not comply with the assigned treatment
comprised 15.2 % (22/145) of the intervention group and 45.4 % (69/152) of the
control group. Thus, the ITT effect would substantially underestimate the true
causal effect of the treatment (that is, antidepressant medication). Then, we applied
the following two SMMs for estimation of the causal treatment effect on the treated:
(i) a one parameter SMM including the main effect only, that is, Z(X, R) = 1; (ii) a





p value of GOF
test
Fischer Proposed
Antidepressant medication: number (%) 123 (84.8) 69 (45.4)
HDRS score: mean ± SD
At baseline 18.93 ± 6.17 17.36 ± 5.62
At follow-up 11.51 ± 7.38 13.55 ± 8.35
Change from the baseline -7.42 ± 6.60 -3.80 ± 7.90
ITT effect (95 % CI) -3.62 (-5.29, -1.95)
1 parameter SMM (95 % CI)
Main effect -7.92 (-12.52, -3.32) 0.770 0.854
2 parameter SMM (95 % CI)
Main effect -8.09 (-12.78, -3.40) 0.974 0.825
Effect modification with baseline HDRS score -0.13 (-1.04, 0.78)
CI confidence interval, HDRS Hamilton depression rating scale, ITT intention-to-treat, PROSPECT
prevention of suicide in primary care elderly: collaborative trial, SD standard deviation, SMM structural
mean model
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two parameter SMM assuming the effect modification with X, that is, Z(X, R) = (1,
X). The baseline covariate X was centered; thus, the main effect parameter for the
model (ii) was interpreted to represent the treatment effect at the mean value for the
covariates. As shown in Table 2, the two SMMs gave much larger effect estimates
than the ITT analysis did, as expected. From the estimation result of the two
parameter SMM, the treatment effect was slightly larger for those with higher
baseline levels of the baseline HDRS score, although the effect was not statistically
significant. We then applied the proposed GOF test using the test statistics V3n(x) in
Sect. 4 as well as the test proposed by Fischer et al. (2011). The p value of the GOF
test was large for the one parameter model (i) for both methods, indicating good
fitting of the main effect model. No difference was observed between the two GOF
tests in this analysis. As noted in Taguri et al. (2014), the larger model (two
parameter model) gave the larger p value for the Fischer et al.’s test.
6 Discussion
In this article, we have proposed a new global GOF test for the parametric part of
the SMMs. The proposed model-checking method is an objective and informative
approach for numerically checking the function form of covariates in SMM.
Simulation studies demonstrate that the proposed test works well in terms of the
type errors and power for both linear and non-linear effect modifications.
Although SMMs and g-estimation always provide a valid test of the no treatment
effect in the presence of non-compliance (Robins 1994), the correct model
specification is a fundamental assumption for consistently estimating the causal
treatment effect. In this regard, assessing the GOF of the candidate SMMs is very
important. Our GOF test and the model selection criterion proposed by Taguri et al.
(2014) can be used as complementary approaches, with the GOF test evaluating the
overall fit and the model selection criterion evaluating the relative fit of candidate
models.
SMMs have been used to handle repeated measures over time as structural nested
mean models (Robins 1994) and related structural distribution models have been
developed for survival outcomes (Mark and Robins 1993; Loeys and Goetghebeur
2003). Recently, Wallace et al. (2016) proposed a model assessment technique
which can detect misspecifications of nuisance functions in SMMs for dynamic
treatment regimens using the property of double robustness in observational studies.
It is interesting to investigate as to how to extend our method to these problems.
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